Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2019 1
2020 1
2021 2
2022 1
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Dytfeld D, Wróbel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski Ł, Końska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Griffith K, Stefka A, Major A, Derman BA, Jakubowiak AJ. Dytfeld D, et al. Among authors: majcherek m. Lancet Oncol. 2023 Feb;24(2):139-150. doi: 10.1016/S1470-2045(22)00738-0. Epub 2023 Jan 12. Lancet Oncol. 2023. PMID: 36642080 Free PMC article. Clinical Trial.
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
Kubicki T, Dytfeld D, Wróbel T, Jamroziak K, Robak P, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski Ł, Zaucha JM, Mikulski D, Czabak O, Lahoud OB, Stefka A, Derman BA, Jakubowiak AJ. Kubicki T, et al. Among authors: majcherek m. Br J Haematol. 2023 Dec;203(5):792-802. doi: 10.1111/bjh.19097. Epub 2023 Sep 10. Br J Haematol. 2023. PMID: 37691005 Clinical Trial.
Significance of HLA-E and its two NKG2 receptors in development of complications after allogeneic transplantation of hematopoietic stem cells.
Siemaszko J, Łacina P, Szymczak D, Szeremet A, Majcherek M, Czyż A, Sobczyk-Kruszelnicka M, Fidyk W, Solarska I, Nasiłowska-Adamska B, Skowrońska P, Bieniaszewska M, Tomaszewska A, Basak GW, Giebel S, Wróbel T, Bogunia-Kubik K. Siemaszko J, et al. Among authors: majcherek m. Front Immunol. 2023 Oct 13;14:1227897. doi: 10.3389/fimmu.2023.1227897. eCollection 2023. Front Immunol. 2023. PMID: 37901227 Free PMC article.
Hemophagocytic Lymphohistiocytosis Secondary to Peripheral T Cell Lymphoma with Rapid Onset and Fatal Progression in a Young Patient: A Case Report and Review of the Literature.
Paluszkiewicz P, Martuszewski A, Majcherek M, Kucharska M, Bogucka-Fedorczuk A, Wróbel T, Czyż A. Paluszkiewicz P, et al. Among authors: majcherek m. Am J Case Rep. 2021 Sep 30;22:e932765. doi: 10.12659/AJCR.932765. Am J Case Rep. 2021. PMID: 34588412 Free PMC article. Review.
The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single-centre real-life experience.
Majcherek M, Kiernicka-Parulska J, Mierzwa A, Barańska M, Matuszak M, Lewandowski K, Komarnicki M, Czyż A. Majcherek M, et al. Scand J Immunol. 2021 Aug;94(2):e13028. doi: 10.1111/sji.13028. Epub 2021 Feb 22. Scand J Immunol. 2021. PMID: 33577137 Free article.
The booster dose of BNT162b2 mRNA vaccine in patients after hematopoietic stem cell transplantation: humoral and clinical response and serological conversion predictors.
Majcherek M, Matkowska-Kocjan A, Szymczak D, Karasek M, Przeorski K, Szeremet A, Kiraga A, Milanowska A, Kuznik E, Kujawa K, Wrobel T, Szenborn L, Czyz A. Majcherek M, et al. Acta Oncol. 2023 Dec;62(12):1939-1941. doi: 10.1080/0284186X.2023.2254923. Epub 2023 Sep 5. Acta Oncol. 2023. PMID: 37669166 No abstract available.
Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience.
Sobas M, Czyż A, Montesinos P, Armatys A, Helbig G, Hołowiecka A, Pluta A, Zarzycka E, Piątkowska-Jakubas B, Majcherek M, Lewandowski K, Gołos A, Paluszewska M, Podhorecka M, Oleksiuk J, Skręt A, Hawrylecka D, Guzicka-Kazimierczak RE, Wątek M, Gromek T, Charliński G, Grosicki S, Holojda J, Miśkiewicz W, Martinez-Cuadrón D, Sanz MA, Wróbel T, Wierzbowska A, Giebel S. Sobas M, et al. Among authors: majcherek m. Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):105-113. doi: 10.1016/j.clml.2019.09.616. Epub 2019 Sep 30. Clin Lymphoma Myeloma Leuk. 2020. PMID: 31874794
11 results